- Mereo BioPharma Group’s stock has appreciated nicely since pricing a highly-dilutive secondary on Feb. 10, 2021.
- Although nearly uncovered by the Street, the company made headlines in December 2020 when it inked a collaboration with Ultragenyx that included $50 million upfront.
- With ongoing negotiations for two other "non-core" assets, data from its two wholly-owned assets due in 2H21, and an impressive roster of 13D/G owners, Mereo merited a deeper dive.
- A full analysis follows in the paragraphs below.
For further details see:
Our Move On Mereo BioPharma